Echocardiography to Screen for Pulmonary Hypertension in CKD

Loading...

Date

2020-12-01

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

50
views
225
downloads

Citation Stats

Attention Stats

Abstract

© 2020 International Society of Nephrology Introduction: Pulmonary hypertension (PH) is a common yet incompletely understood complication of chronic kidney disease (CKD). Although transthoracic echocardiogram is commonly used to noninvasively estimate PH, it has not been validated in a CKD population. We investigated the utility of this diagnostic tool for CKD-associated PH in a large right heart catheterization (RHC) cohort. Methods: We reviewed RHC and echocardiography data in 4036 patients (1714 with CKD) obtained between 2011 and 2014 at a single center. We used multivariate regression to determine the associations of echocardiography measurements with PH, and evaluated whether estimated glomerular filtration rate (eGFR) modified these associations. Using internal validation, we sequentially added measurements to predictive models and analyzed the incremental predictive performance using the change in the area under the receiver operating characteristic curve (ΔAUC) and net reclassification improvement. Results: The echocardiography measurements most strongly associated with the diagnosis of PH included tricuspid regurgitant velocity (TRV), tricuspid annular plane systolic excursion (TAPSE), right atrial pressure, diastolic dysfunction, and right ventricular function. Among these measurements, eGFR significantly modified the associations of TAPSE and diastolic dysfunction with the diagnosis of PH. The model consisting of a combination of TRV, right atrial pressure, and TAPSE most accurately predicted the diagnosis of PH in a CKD population (AUC 0.82). Conclusions: The optimal model to predict PH diagnosis included TRV, right atrial pressure, and TAPSE. Since TAPSE more strongly associated with PH in the CKD population, these findings support a CKD-specific approach to the development of noninvasive screening algorithms for PH.

Department

Description

Provenance

Subjects

Citation

Published Version (Please cite this version)

10.1016/j.ekir.2020.09.033

Publication Info

Edmonston, Daniel L, Sudarshan Rajagopal and Myles Wolf (2020). Echocardiography to Screen for Pulmonary Hypertension in CKD. Kidney International Reports, 5(12). pp. 2275–2283. 10.1016/j.ekir.2020.09.033 Retrieved from https://hdl.handle.net/10161/22283.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Edmonston

Daniel Edmonston

Assistant Professor of Medicine

My primary research focus lies at the intersection of kidney and cardiovascular disease including pulmonary hypertension, heart failure, and atherosclerotic disease in patients with chronic kidney disease. 

Rajagopal

Sudarshan Rajagopal

Associate Professor of Medicine

I am a physician-scientist with a research focus on G protein-coupled receptor signaling in inflammation and vascular disease and a clinical focus on pulmonary vascular disease, as I serve as Co-Director of the Duke Pulmonary Vascular Disease Center. My research spans the spectrum from clinical research in pulmonary vascular disease, to translational research in cardiovascular disease, to the basic science of receptor signaling.

Our basic science research focuses on understanding and untapping the signaling potential of G protein-coupled receptors (GPCRs) to regulate inflammation in vascular disease. GPCRs are the most common transmembrane receptors in the human genome (over 800 members) and are some of the most successful targets for drug therapies. While it has been known for some time that these receptors signal through multiple downstream effectors (such as heterotrimeric G proteins and multifunctional beta arrestin adapter proteins), over the past decade it has been better appreciated that these receptors are capable of signaling with different efficacies to these effectors, a phenomenon referred to as “biased agonism”. Ligands can be biased, by activating different pathways from one another, and receptors can be biased, by signaling to a limited number of pathways that are normally available to them. Moreover, this phenomenon also appears to be common to other transmembrane and nuclear receptors. While a growing number of biased agonists acting at multiple receptors have been identified, there is still little known regarding the mechanisms underlying biased signaling and its physiologic impact. We use multiple approaches to probe these signaling mechanisms, including in-house pharmacological assays, advanced phosphoproteomics and single cell RNA sequencing.

Our translational research is focused on studying signaling in different forms of pulmonary hypertension (PH), a disease of the pulmonary vasculature that results in right heart failure. We have identified novel molecular mechanisms that contribute to the development of pulmonary arterial hypertension (PAH), a disease of the pulmonary arterioles. We have also used single cell RNA sequencing to identify the cell types and signaling pathways that contribute to chronic thromboembolic pulmonary hypertension (CTEPH). 

Lastly, our clinical research program focuses on the application of novel imaging technologies for diagnosis, prognosis and management of PH. Most notably, this includes the application of hyperpolarized Xenon MRI, in collaboration with Dr. Bastiaan Driehuys in the Department of Radiology, to characterizing the physiological basis of gas exchange and hemodynamic abnormalities across all forms of PH. In collaboration with Dr. Fawaz Alenezi, we have applied advanced echo approaches for the management of PH.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.